Navigation Links
Amicus Therapeutics Presents Data from Clinical Ex Vivo Response Study and Phase 1 Studies of AT2220
Date:3/13/2008

atment of a range of human genetic diseases. Pharmacological chaperone technology involves the use of small molecules that selectively bind to and stabilize proteins in cells, leading to improved protein folding and trafficking, and increased activity. Amicus is initially targeting lysosomal storage disorders, which are severe, chronic genetic diseases with unmet medical needs. Amicus has completed Phase 2 clinical trials of Amigal(TM) for the treatment of Fabry disease and is conducting Phase 2 clinical trials of Plicera(TM) for the treatment of Gaucher disease. The Company recently completed Phase I clinical trials of AT2220 for the treatment of Pompe disease.

Forward-Looking Statements

Amicus cautions you that statements included in this press release that are not a description of historical facts are "forward-looking statements" within the meaning of Section 21E of the Private Securities Litigation Reform Act of 1995. Words such as, but not limited to, "look forward to," "believe," "expect," "anticipate," "estimate," "intend," "plan," "targets," "likely," "will," "would," "should" and "could," and similar expressions or words identify forward-looking statements. Such forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties. The inclusion of forward-looking statements should not be regarded as a representation by Amicus that any of its plans will be achieved. Any or all of the forward-looking statements in this press release may turn out to be wrong. They can be affected by inaccurate assumptions Amicus might make or by known or unknown risks and uncertainties. For example, with respect to statements regarding the potential progress and results of clinical trials, actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in the business of Amicus, including, without limitation: and the effect of the completion
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Amicus Therapeutics to Present at the 26th Annual JPMorgan Healthcare Conference
2. Amicus Therapeutics Announces Positive Results From Two Phase 1 Clinical Studies of AT2220 for Pompe Disease
3. Amicus Therapeutics Announces Plans to Present Phase 1 Data for AT2220 for Pompe Disease
4. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
5. Ception Therapeutics Initiates Phase II/III Clinical Trial for Its Lead Product Reslizumab in Eosinophilic Esophagitis (EE) in Children
6. Cell Therapeutics, Inc. (CTI) Submits European Marketing Authorization Application for XYOTAX(TM)
7. InteKrin Therapeutics Announces Initiation of Phase 2b Study in Type 2 Diabetes with INT131
8. Oncology Drug Development Update - Molecular Profiling Redefines the Nature of Malignancy and Increases the Adoption of Targeted Therapeutics
9. TorreyPines Therapeutics Announces Strategic Plan with Focus on Clinical Development Activities to Maximize Value of Versatile Lead Compounds
10. Horizon Therapeutics Completes Enrollment in Phase 3 Trials for Lead Product Candidate HZT-501
11. Multiple Dose Clinical Trial of TorreyPines Therapeutics Tezampanel Demonstrates Compound is Safe and Well-Tolerated
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2015)... , April 17, 2015  In Detroit, where three ... mortality rate is two and one half times of the ... 6 of 10 infants that die in Detroit ... sobering statistics that Covenant Community Care, a faith-based, charitable non-profit ... poised to change thanks to a charitable donation by Konica ...
(Date:4/17/2015)... , April 17, 2015  Over the next five years, ... to grow, with ArcView predicting that 14 more states will ... marijuana. The U.S. market for legal cannabis grew 74 percent ... 2013. Analysts project the market could grow more than fourfold ... states soften their stance on marijuana. Cannabiz Mobile ...
(Date:4/17/2015)... and Markets ( http://www.researchandmarkets.com/research/7qs3dw/corporate ) has announced ... in 2014 - a Perspective of Diabetes Patient Groups ... This independent study, funded by the author, represents ... in diabetes on the corporate reputation of 14 individual ... whole) in 2014. The results from the respondent diabetes ...
Breaking Medicine Technology:Covenant Community Care to Receive Donated SONIMAGE P3 Handheld Ultrasound from Konica Minolta Medical Imaging 2Covenant Community Care to Receive Donated SONIMAGE P3 Handheld Ultrasound from Konica Minolta Medical Imaging 3Covenant Community Care to Receive Donated SONIMAGE P3 Handheld Ultrasound from Konica Minolta Medical Imaging 4Cannabiz Mobile Analyst Brief: Next Big Thing by Torus IR Issued by BrokerBank Securities, Inc. 2Perspective of Diabetes Patient Groups on the Corporate Reputation of Pharma in 2014: 130 patient groups with an interest in diabetes from 34 countries 2Perspective of Diabetes Patient Groups on the Corporate Reputation of Pharma in 2014: 130 patient groups with an interest in diabetes from 34 countries 3Perspective of Diabetes Patient Groups on the Corporate Reputation of Pharma in 2014: 130 patient groups with an interest in diabetes from 34 countries 4Perspective of Diabetes Patient Groups on the Corporate Reputation of Pharma in 2014: 130 patient groups with an interest in diabetes from 34 countries 5
... 23, 2007 /PRNewswire-FirstCall/ -- Shire plc,announced that ... non-oral medication approved for treatment of,Attention Deficit ... 12 years, provided significant improvement in symptom ... 12-month open-label,study presented at the American Psychiatric ...
... Underscores Impact of Disease on Work Status and,Productivity, ... at Digestive Disease Week(R) 2007 (DDW), from,long-term extensions ... 2) show that subjects with moderately to severely ... in the blinded phase of the trials maintained,improvement ...
Cached Medicine Technology:12-Month Study Demonstrated Tolerability and Efficacy of DAYTRANA,(methylphenidate transdermal system) 212-Month Study Demonstrated Tolerability and Efficacy of DAYTRANA,(methylphenidate transdermal system) 312-Month Study Demonstrated Tolerability and Efficacy of DAYTRANA,(methylphenidate transdermal system) 412-Month Study Demonstrated Tolerability and Efficacy of DAYTRANA,(methylphenidate transdermal system) 512-Month Study Demonstrated Tolerability and Efficacy of DAYTRANA,(methylphenidate transdermal system) 612-Month Study Demonstrated Tolerability and Efficacy of DAYTRANA,(methylphenidate transdermal system) 712-Month Study Demonstrated Tolerability and Efficacy of DAYTRANA,(methylphenidate transdermal system) 812-Month Study Demonstrated Tolerability and Efficacy of DAYTRANA,(methylphenidate transdermal system) 9Long-Term Extension of Ulcerative Colitis Study Shows Remicade,Responders Maintained Improvement Through Two Years of Follow-Up 2Long-Term Extension of Ulcerative Colitis Study Shows Remicade,Responders Maintained Improvement Through Two Years of Follow-Up 3Long-Term Extension of Ulcerative Colitis Study Shows Remicade,Responders Maintained Improvement Through Two Years of Follow-Up 4Long-Term Extension of Ulcerative Colitis Study Shows Remicade,Responders Maintained Improvement Through Two Years of Follow-Up 5Long-Term Extension of Ulcerative Colitis Study Shows Remicade,Responders Maintained Improvement Through Two Years of Follow-Up 6Long-Term Extension of Ulcerative Colitis Study Shows Remicade,Responders Maintained Improvement Through Two Years of Follow-Up 7Long-Term Extension of Ulcerative Colitis Study Shows Remicade,Responders Maintained Improvement Through Two Years of Follow-Up 8Long-Term Extension of Ulcerative Colitis Study Shows Remicade,Responders Maintained Improvement Through Two Years of Follow-Up 9
(Date:4/17/2015)... April 17, 2015 As a board-certified ... his new offering of platelet-rich plasma (PRP) ... (MOSM) is known for its world-class care of ... extensive surgical experience lacking in many other physicians offering ... treatments are utilized for pain management and rehabilitation. Dr. ...
(Date:4/17/2015)... 2015 Baptist Health and The University ... partnership agreement designed to transform oncology care in northeast ... agreed to create a joint cancer program to enhance ... research. Baptist MD Anderson Cancer Center is anticipated to ... destination for highly coordinated, multidisciplinary cancer care for adults ...
(Date:4/17/2015)... (PRWEB) April 17, 2015 Connie Casad, ... and functional medicine advocate with 30 years of practice ... be adding another level of service for her patients ... website of 10 recommended wellness books with a brief ... asked to explain her interest in providing this service, ...
(Date:4/17/2015)... 17, 2015 Oxytocin is ... pituitary and thought to help mothers bond to their ... further substantiate this, new studies performed, at NYU Langone ... and reported by Medical News Today on April 16, ... over maternal social behavior. The study reveals that, when ...
(Date:4/17/2015)... NY (PRWEB) April 17, 2015 Ticket Down is ... for their 2015 Summer Tour. , The life of last-minute show ... see the popular group perform during the early part of 2015, ... “I Will Wait,” “Little Lion Man,” “The Cave,” and “Believe,” will ... off on June 2 at MCU Park at Coney Island in ...
Breaking Medicine News(10 mins):Health News:Platelet-Rich Plasma, Stem Cell Therapy Now Offered By Dr. Meier At MOSM in Beverly Hills, California 2Health News:Platelet-Rich Plasma, Stem Cell Therapy Now Offered By Dr. Meier At MOSM in Beverly Hills, California 3Health News:Baptist Health and MD Anderson Finalize Agreement to Transform Cancer Care in Region 2Health News:Baptist Health and MD Anderson Finalize Agreement to Transform Cancer Care in Region 3Health News:Connie Casad, M.D. Provides Patients Recommended List of Wellness Books on Website 2Health News:Oxytocin Now Found to Help Diet Doc Patients Whose Weight Has Gotten out of Control Due to Emotional Eating Disorders 2Health News:Oxytocin Now Found to Help Diet Doc Patients Whose Weight Has Gotten out of Control Due to Emotional Eating Disorders 3Health News:Mumford and Sons Tickets in Clarkston/Detroit, Raleigh, Columbia/Baltimore, Chicago, Mansfield/Boston, Brooklyn, Calgary and Edmonton Now On Sale 2
... to a report published in the December issue of the ... residents improved their knowledge of health care business concepts and ... expectation is for residents to "demonstrate an awareness of and ... as well as the ability to call effectively on other ...
... of synthetic molecules to fish for disease-specific antibodies, researchers have ... simple blood test. The same methodology might lead to blood ... the January 7th issue of the journal Cell , ... disease, it suggests it is a pretty general platform that ...
... study to date of "Sarcoid Like" Granulomatous Pulmonary Disease in ... of the condition was increased in this group as compared ... published online in the American Journal of Industrial Medicine ... responders who had an initial exam in the Mount Sinai ...
... the first robotic assisted surgery for prostate cancer in ... Vattikuti Institute. Today, the majority prostate of cancer ... than 6,000 procedures have been performed during the past ... field will meet at the world,s largest medical robotic ...
... most widely produced fruit in the world and now ... nutrient which could tackle the onset of vascular diseases. ... & Food Research , reveals that an extracted compound, ... led by Dr Teruo Kawada, from Kyoto University and ...
... brain against developing Alzheimer,s and other forms of dementia, according ... study, published in the academic journal Phytomedicine , also ... in protecting the body against cancer., Led by Dr Ed ... properties of green tea which have previously been shown ...
Cached Medicine News:Health News:Web-based curriculum improves surgical residents' knowledge of health care business 2Health News:A blood test for Alzheimer's disease? 2Health News:A blood test for Alzheimer's disease? 3Health News:Study of 'sarcoid-like' granulomatous pulmonary disease finds elevated rates in WTC responders 2Health News:Study of 'sarcoid-like' granulomatous pulmonary disease finds elevated rates in WTC responders 3Health News:10 years later: Robotic surgery for prostate cancer 2Health News:Protective properties of green tea uncovered 2
Biopro rimmed acetabular is manufactured from titanium and is porous coated on the outside of its shell. The rimmed acetabular accommodates a polyethylene inert....
The Plasmacup SC satisfies two important requirements: high primary stability and a low friction bearing surface....
The cementless acetabular shells form part of the Mallory head range of femoral and acetabular implants....
Trident Hemispherical Acetabular Shells are a true hemispherical shape designed to achieve press-fit fixation by under-reaming the acetabulum....
Medicine Products: